HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial

Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells

(2014) Marcella Sarzotti-Kelsoe et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

(2014) Susan Zolla-Pazner et al.   PLoS One

Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults

(2013) Peter Hayes et al.   Clinical and Vaccine Immunology

Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1

(2013) Marcella Sarzotti-Kelsoe et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection

(2013) Holly Janes et al.   JOURNAL OF INFECTIOUS DISEASES

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

(2013) Claudia Marcela Diaz-Montero et al.   Journal of Translational Medicine

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

(2013) Scott M. Hammer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

(2013) Raphael Gottardo et al.   PLoS One

Detection of HIV-1 Neutralizing Antibodies in a Human CD4+/CXCR4+/CCR5+ T-Lymphoblastoid Cell Assay System

(2013) Robert J. McLinden et al.   PLoS One

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

(2013) G. D. Tomaras et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients

(2012) Alexandre Harari et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

(2012) D. C. Montefiori et al.   JOURNAL OF INFECTIOUS DISEASES

Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)

(2012) Dan H. Barouch et al.   JOURNAL OF INFECTIOUS DISEASES

Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8+T Cells Induced by Different Adenovirus Vectors

(2012) Wendy G. Tan et al.   JOURNAL OF VIROLOGY

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

(2012) Dan H. Barouch et al.   NATURE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens

(2012) Silvia Ratto-Kim et al.   PLoS One

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection

(2012) Gareth Betts et al.   PLoS One

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

(2011) Nicole Frahm et al.   JOURNAL OF CLINICAL INVESTIGATION

HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable

(2011) S. C. De Rosa et al.   JOURNAL OF IMMUNOLOGY

Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles

(2011) Paul A. Goepfert et al.   JOURNAL OF INFECTIOUS DISEASES

Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals

(2011) G. D. Tomaras et al.   JOURNAL OF VIROLOGY

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

(2011) Gavin J. Churchyard et al.   PLoS One

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects☆☆☆

(2011) Michael C. Keefer et al.   VACCINE

The Role of Antibodies in HIV Vaccines

(2010) John R. Mascola et al.   Annual Review of Immunology

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)

(2010) Laurence Peiperl et al.   PLoS One

Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC

(2010) Tara G. Edmonds et al.   VIROLOGY

CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials

(2010) Kenneth F. Schulz et al.   PLOS MEDICINE

Heterologous prime–boost vaccination

(2009) Shan Lu   CURRENT OPINION IN IMMUNOLOGY

Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies

(2009) M. S. Seaman et al.   JOURNAL OF VIROLOGY

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Simultaneous Evaluation of the Magnitude and Breadth of a Left- and Right-Censored Multivariate Response, With Application to HIV Vaccine Development

(2009) Yunda Huang et al.   Statistics in Biopharmaceutical Research

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

(2008) Frances H. Priddy et al.   CLINICAL INFECTIOUS DISEASES

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

(2008) Alexandre Harari et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

(2008) G. D. Tomaras et al.   JOURNAL OF VIROLOGY

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET

EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium

(2008) Pierre-Alexandre Bart et al.   VACCINE

EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone

(2008) Sheena McCormack et al.   VACCINE